Gorlia, Thierry

Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma

Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine

Glioma Diagnosis and TreatmentPARP inhibition in cancer therapy

Cited by 21,807

MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma

Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine

Glioma Diagnosis and TreatmentPARP inhibition in cancer therapy

Cited by 7,405

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

Stupp, R., Hegi, M. E., Gorlia, T., Erridge, S. C., Perry, J., Hong, Y.-K., Aldape, K. D., Lhermitte, B., Pietsch, T., Grujicic, D., et al. (2014) · The Lancet Oncology

Glioma Diagnosis and TreatmentPARP inhibition in cancer therapy

Cited by 1,052

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

Baumert, B. G., Hegi, M. E., van den Bent, M. J., von Deimling, A., Gorlia, T., Hoang-Xuan, K., Brandes, A. A., Kantor, G., Taphoorn, M. J. B., Hassel, M. B., et al. (2016) · The Lancet Oncology

Glioma Diagnosis and TreatmentAcute Myeloid Leukemia Research

Cited by 495

Transcriptome analysis reveals tumor microenvironment changes in glioblastoma

Hoogstrate, Y., Draaisma, K., Ghisai, S. A., van Hijfte, L., Barin, N., de Heer, I., Coppieters, W., van den Bosch, T. P. P., Bolleboom, A., Gao, Z., et al. (2023) · Cancer Cell

Glioma Diagnosis and TreatmentSingle-cell and spatial transcriptomics

Cited by 240

Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: A report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial

Dubbink, H. J., Atmodimedjo, P. N., Kros, J. M., French, P. J., Sanson, M., Idbaih, A., Wesseling, P., Enting, R., Spliet, W., Tijssen, C., et al. (2016) · Neuro-Oncology

Glioma Diagnosis and TreatmentAcute Myeloid Leukemia Research

Cited by 163

Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations

Tesileanu, C. M. S., Vallentgoed, W. R., Sanson, M., Taal, W., Clement, P. M., Wick, W., Brandes, A. A., Baurain, J. F., Chinot, O. L., Wheeler, H., et al. (2021) · Acta Neuropathologica

Glioma Diagnosis and TreatmentAcute Myeloid Leukemia Research

Cited by 62